Evidence map›Paper›PMID 42725368›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026

Emergence and spread of NA-I223V and NA-S247N double-mutant A(H1N1)pdm09 influenza viruses with reduced oseltamivir susceptibility in the Netherlands and beyond, 2023 to 2026.

Zandra Felix Garza, Dirk Eggink, Mariam Bagheri, Sharon van den Brink, Gabriel Goderski, Mark Pronk, Pascal Lexmond, Mariëtte Hooiveld, Rianne van Gageldonk-Lafeber, Björn Koel and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zandra Felix GarzaCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Dirk EgginkCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Mariam BagheriCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Sharon van den BrinkCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Gabriel GoderskiCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Mark PronkDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, The Netherlands.
Pascal LexmondDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, The Netherlands.
Mariëtte HooiveldNivel (Netherlands institute for health services research), Utrecht, The Netherlands.
Rianne van Gageldonk-LafeberCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
Björn KoelDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, The Netherlands.
Ron FouchierDepartment of Viroscience, Erasmus Medical Centre, Rotterdam, The Netherlands.
Adam MeijerCentre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2023/24, A(H1N1)pdm09 influenza viruses with neuraminidase (NA)-S247N emerged in NA-clade C.5.3.3 carrying NA-I223V, spread internationally, then faded. Such double mutants reappeared sporadically in 2024/25. They expanded again in 2025/26 in NA-clade D.3 viruses carrying NA-S247N after acquiring NA-I223V in Europe - notably Spain, the Netherlands, Finland and France, and beyond. Dutch double mutants from both seasons showed median 12- and 13-fold reduced inhibition by oseltamivir. These findings underscore the need for ongoing genomic and phenotypic monitoring of antiviral susceptibility.

Indexed as

Antiviral AgentsDrug Resistance, ViralInfluenza A Virus, H1N1 SubtypeInfluenza, HumanNeuraminidaseOseltamivirHumansMicrobial Sensitivity TestsMutationNetherlandsViral ProteinsAntiviral AgentsNeuraminidaseOseltamivirViral ProteinsA(H1N1)pdm09 influenza virusantiviral susceptibilitygenomicoseltamivirphenotypiczanamivir

Identifiers

PMID42725368
PMCPMC13570233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.